Imiquimod: An immune response modifier in the treatment of precancerous skin lesions and skin cancer

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 11, 2007, Pages 1743-1755

  Papadavid, Evangelia ^a,d   Stratigos, Alexandros J ^b   Falagas, Matthew E ^c,d  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

Author keywords

Actinic keratosis; Basal cell carcinoma; Imiquimod; Off label use; Precancerous lesions; Skin cancer

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; ALPHA INTERFERON; B7 ANTIGEN; BACTERIUM LYSATE; BCG VACCINE; CD40 ANTIGEN; CD86 ANTIGEN; DIPHENCYPRONE; FLUOROURACIL; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MYCOBACTERIUM VACCINE; MYELOID DIFFERENTIATION FACTOR 88; PLACEBO; SQUARIC ACID DIBUTYL ESTER; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ACTINIC KERATOSIS; ANAPHYLACTOID PURPURA; ANGIONEUROTIC EDEMA; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; APPLICATION SITE BURNING; APPLICATION SITE DRYNESS; APPLICATION SITE EDEMA; APPLICATION SITE ERYTHEMA; APPLICATION SITE EXCORIATION; APPLICATION SITE PAIN; APPLICATION SITE PIGMENTATION CHANGE; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; APPLICATION SITE SCABBING; APPLICATION SITE ULCER; APPLICATION SITE VESICLE; ARTICLE; BASAL CELL CARCINOMA; BLOOD CELL COUNT; BOWEN DISEASE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CARBON DIOXIDE LASER; CARDIOVASCULAR DISEASE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONDYLOMA; COST EFFECTIVENESS ANALYSIS; CRYOTHERAPY; CYTOKINE PRODUCTION; DESICCATION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; ERYTHEMA; ERYTHEMA MULTIFORME; ESTHETICS; EXFOLIATIVE DERMATITIS; FOOD AND DRUG ADMINISTRATION; HUMAN; INNATE IMMUNITY; LIVER DYSFUNCTION; LOW LEVEL LASER THERAPY; MELANOMA; MENTAL DISEASE; MONOTHERAPY; NONHUMAN; OFF LABEL DRUG USE; PATIENT COMPLIANCE; PEMPHIGUS FOLIACEUS; PLEIOTROPY; POSTMARKETING SURVEILLANCE; PRECANCER; PROTEIN EXPRESSION; PSORIASIS; RECURRENCE RISK; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN CANCER; SKIN CARCINOMA; SKIN INDURATION; SKIN MANIFESTATION; SKIN SURGERY; SKIN TOXICITY; TUMOR IMMUNITY; URINARY TRACT DISEASE; VITILIGO;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANIMALS; CARCINOMA, BASAL CELL; HUMANS; PHOTOSENSITIVITY DISORDERS; PRECANCEROUS CONDITIONS; SKIN DISEASES; SKIN NEOPLASMS;

EID: 34548137761     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.11.1743     Document Type: Article

References (101)

1. GUPTA AK, DAVEY V, MCPHAIL H: Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: critical review and meta-analysis of efficacy studies. J. Cutan. Med. Surg. (2005) 9(5):209-214.
2. TANGHETTI W, WERSCHKER P: Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratosis on the face and scalp. J. Drugs Dermatol. (2007) 6(2):144-147.
3. NAYLOR M: Imiquimod and superficial skin cancers. J. Drugs Dermatol. (2005) 4(5):598-606.
4. WOODMANSEE C, PILLOW J, SKINNER RB Jr: The role of topical immune response modifiers in skin cancer. Drugs (2006) 66(13):1657-1664.
5. SCHON MP, SCHON M: The small-molecule immune response modifier imiquimod - its mode of action and clinical use in the treatment of skin cancer. Expert Opin. Ther. Targets (2006) 10(1):69-76.
6. BERMAN B, VILLA AM, RAMIREZ CC: Mechanisms of action of new treatment modalities for actinic keratosis. J. Drugs Dermatol. (2006) 5(2):167-173.
7. MASIHI KN: Immunomodulatory agents for prophylaxis and therapy of infections. Int. J. Antimicrob. Agents (2000) 14(3):181-191.
8. BUCKLEY DA, DU VIVIER AW: The therapeutic use of topical contact sensitizers in benign dermatoses. Br. J. Dermatol. (2001) 145(3):385-405.
9. HENGGE UR, BENNINGHOFF B, RUZICKA T, GOOS M: Topical immunomodulators-progress towards treating inflammation, infection, and cancer. Lancet Infect. Dis. (2001) 1(3):189-198.
10. HENGGE UR, RUZICKA T: Topical immunomodulation in dermatology: potential of Toll-like receptor agonists. Dermatol. Surg. (2004) 30(8):1101-1112.
11. SCHILLER M, METZE D, LUGER TA, GRABBE S, GUNZER M: Immune response modifiers - mode of action. Exp. Dermatol. (2006) 15(5):331-341.
12. VIDAL D: Topical imiquimod: mechanism of action and clinical applications. Mini. Rev. Med. Chem. (2006) 6(5):499-503.
13. STANLEY MA: Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin. Exp. Dermatol. (2002) 27(7):571-577.
14. SAUDER DN: Immunomodulatory and pharmacologic properties of imiquimod. J. Am. Acad. Dermatol. (2000) 43(1 Part 2):S6-S11.
15. SIDKY YA, BORDEN EC, WEEKS CE, REITER MJ, HATCHER JF, BRYAN GT: Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res. (1992) 52(13):3528-3533.
16. BERMAN B, PEREZ OA, ZELL D: Immunological strategies to fight skin cancer. Skin Ther. Lett. (2006) 11(5):1-7.
17. REITER MJ, TESTERMAN TL, MILLER RL, WEEKS CE, TOMAI MA: Cytokine induction in mice by the immunomodulator imiquimod. J. Leukoc. Biol. (1994) 55(2):234-240.
18. TESTERMAN TL, GERSTER JF, IMBERTSON LM et al.: Cytokine induction by the immunomodulators imiquimod and S-27609. J. Leukoc. Biol. (1995) 58(3):365-372.
19. SUZUKI H, WANG B, SHIVJI GM et al.: Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J. Invest. Dermatol. (2000) 114(1):135-141.
20. IMBERTSON LM, BEAURLINE JM, COUTURE AM et al.: Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J. Invest. Dermatol. (1998) 110(5):734-739.
21. LEMAITRE B, NICOLAS E, MICHAUT L, REICHHART JM, HOFFMANN JA: The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell (1996) 86(6):973-983.
22. MEDZHITOV R, PRESTON-HURLBURT P, JANEWAY CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature (1997) 388(6640):394-397.
23. ITO T, AMAKAWA R, KAISHO T et al.: Intefferon-α and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J. Exp. Med. (2002) 195(11):1507-1512.
24. GORDEN KB, GORSKI KS, GIBSON SJ et al.: Synthetic TLR agonists reveal functional differences between human TLR7 and TLRS. J. Immunol. (2005) 174(3):1259-1268.
25. WAGNER TL, AHONEN CL, COUTURE AM et al.: Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol. (1999) 191(1):10-19.
26. BURNS RP Jr, FERBEL B, TOMAI M, MILLER R, GASPARI AA: The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clin. Immunol. (2000) 94(1):13-23.
27. UROSEVIC M, MAIER T, BENNINGHOFF B, SLADE H, BURG G, DUMMER R: Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch. Dermatol. (2003) 139(10):1325-1332.
28. SCHON MP, SCHON M, KLOTZ KN: The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J. Invest. Dermatol. (2006) 126(6):1338-1347.
29. MEYER T, NINDL I, SCHMOOK T, ULRIGH C, STERRY W, STOCKFLETH E: Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures. Br. J. Dermatol. (2003) 149 (66):9-14.
30. SCHON MP, WIENRICH BG, DREWNIOK C et al.: Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J. Invest. Dermatol. (2004) 122(5):1266-1276.
31. LYSA B, TARTLER U, WOLF R et al.: Gene expression in actinic keratoses: pharmacological modulation by imiquimod. Br. J. Dermatol. (2004) 151(6):1150-1159.
32. BERMAN B, SULLIVAN T, DE ARAUJO T, NADJI M: Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle. Br. J. Dermatol. (2003) 149(66):59-61.
33. SCHON M, BONG AB, DREWNIOK C et al.: Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J. Natl. Cancer Inst. (2003) 95(15):1138-1149.
34. MILLER R: Imiquimod stimulates innate and cell mediated immunity which controls virus infections and tumors. Int. J. Dermatol. (2002) 41(1):3-6.
35. BUATES S, MATLASHEWSKI G: Identification of genes induced by a macrophage activator, S-28463, using gene expression array analysis. Antimicrob. Agents Chemother. (2001) 45(4):1137-1142.
36. UROSEVIC M, OBERHOLZER PA, MAIERT et al.: Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-α? Clin. Cancer Res. (2004) 10(15):4959-4970.
37. MILLER RL, GERSTER JF, OWENS ML, SLADE HB, TOMAI MA: Imiquimod applied topically: a novel immune response modifier and new class of drug. Int. J. Immunopharmacol. (1999) 21(1):1-14.
38. BISHOP GA, HSING Y, HOSTAGER BS, JALUKAR SV, RAMIREZ LM, TOMAI MA: Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848. J. Immunol. (2000) 165(10):5552-5557.
39. LI VW, LI WW, TALCOTT KE, ZHAI AW: Imiquimod as an antiangingenic agent. J. Drugs Dermatol. (2005) 4(6):708-717.
40. MAJEWSKI S, MARCZAK M, MLYNARCZYK B, BENNINGHOFF B, JABLONSKA S: Imiquimod is a strong inhibitor of tumor cell-induced angingenesis. Int. J. Dermatol. (2005) 44(1):14-19.
41. ARANY I, TYRING SK, STANLEY MA et al.: Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antiviral Res. (1999) 43(1):55-63.
42. HURWITZ DJ, PINCUS L, KUPPER TS: Imiquimod: a topically applied link between innate and acquired immunity. Arch. Dermatol. (2003) 139(10):1347-1350.
43. KANNEGANTI TD, OZOREN N, BODY-MALAPEL M et al.: Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature (2006) 440(7081):233-236.
44. SLADE HB, OWENS ML, TOMAI MA et al.: Imiquimod 5% cream (Aldara). Expert Opin. Investig. Drugs (1998) 7:437-449.
45. HARRISON LI, SKINNER SL, MARBURY TC et al.: Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms. Arch. Dermatol. Res. (2004) 296(1):6-11.
46. OWENS ML, BRIDSON WE, SMITH SL, MYERS JA, FOX TL, WELLS TM: Percutaneous penetration of Aldara cream, 5% during the topical treatment of genital and perianal warts. Prim. Care Update Obstet. Gyns. (1998) 5(4):151.
47. WEEKS CE, GIBSON SJ: α-interferon induction in human blood cell culture by immunomodulator candidate R-837. J. Interferon Res. (1989) 9(Suppl. 2):S215 (Abstract).
48. KONO T, KONDO S, PASTORE S et al.: Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression. Lymphokine Cytokine Res. (1994) 13(2):71-76.
49. BEUTNER KR, GEISSE JK: Imiquimod - an immune response modifier for the treatment of genital warts. Today's Ther. Trends (1997) 15(3):165-178.
50. TYRING SK, ARANY I, STANLEY MA et al.: A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J. Infect. Dis. (1998) 178(2):551-555.
51. KAIDBEY K, OWENS M, LIBERDA M, SMITH M: Related articles, links safety studies of topical imiquimod 5% cream on normal skin exposed to ultraviolet radiation. Toxicology (2002) 178(2):175-182.
52. LEBWOHL M, DINEHART S, WHITING D et al.: Imiquimod 5% cream for the treatment of actinic keratosis: results from two Phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J. Am. Acad. Dermatol. (2004) 50(5):714-721.
53. KORMAN N, MOY R, LING M et al.: Dosing with imiquimod 5% cream 3 times per week for the treatment of actinic keratosis: results of two Phase III, randomised, double blind, parallel group, vehicle controlled trials. Arch. Dermatol. (2005) 141(4):467-473.
54. STOCKFLETH E, MEYER T, BENNINGHOFF B et al.: A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch. Dermatol. (2002) 138(11):1498-1502.
55. SZEIMIES RM, GERRITSEN MJ, GUPTA G et al.: Imiquimod 5% cream for the treatment of actinic keratosis: results from a Phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J. Am. Acad. Dermatol. (2004) 51(4):547-555.
56. FALAGAS M, ANGELOUSI A, PEPPAS G: Imiquimod for the treatment of actinic keratosis: a meta-analysis of randomized controlied trials. J. Am. Acad. Dermatol. (2006):537-538.
57. CHEN K, YAP LM, MARKS R et al.: Short course therapy with 5% imiquimod cream for solar keratoses: a randomized controlled trial. Aust. J. Dermatol. (2003) 44(4):250-255.
58. SALASCHE SJ, LEVINE N, MORRISON L: Cycle therapy of actinic kerarosis of the face and scalp with 5% topical imiquimod cream: an open label trial. J. Am. Acad. Dermatol. (2002) 47(4):571-577.
59. LEE PK, HARWELL WB, LOVEN KH et al.: Long term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream. Dermatol. Surg. (2005) 31(6):659-664.
60. STOCKFLETH E, CHRISTOPHERS E, BENNINGHOFF B, STERRY W: Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch. Dermatol. (2004) 140(12):1542.
61. ULRICH C, BUSCH JO, MEYER T et al.: Successful treatment of multiple actinic keratosis in organ transplant patients with topical imiquimod 5% cream. Br. J. Dermatol. (2006) 155(2):451-454.
62. BEUTNER KR, GEISSE JK, HELMAN D et al.: Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J. Am. Acad. Dermatol. (1999) 416:1002-1007.
63. GEISSE JK, RICH P, PANDYA A et al.: Imiquimod 5% cream for the treatment of superficial basal cell cardnoma: a double-blind, randomized, vehicle-controlled study. J. Am. Acad. Dermatol. (2002) 47(3):390-398.
64. GEISSE J, CARO I, LINDHOLM J, GOLITZ L, STAMPONE P, OWENS M: Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results form two Phase III, randomized, vehicle-controlled studies. J. Am. Acad. Dermatol. (2004) 50:722-733.
65. MARKS R, GEBAUER K, SHUMACK S et al.; AUSTRALASIAN MULTICENTRE TRIAL GROUP: Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-wcek dose-response trial. J. Am. Acad. Dermatol. (2001) 44(5):807-813.
66. SCHULZE HJ, CRIBIER B, REQUENA J et al.: Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled Phase III study in Europe. Br. J. Dermatol. (2005) 152:939-947.
67. GOLLNICK H, BARONA CG, FRANK RGJ et al.: Recurrence rate of superficial BCC following successful treatment with imiquimod 5% cream: interim 2 year results from an on going 5 year follow up study. Eur. J. Dermatol. (2005) 15(5):374-381.
68. STERRY W, RUZICKA T, HERRERA E et al.: Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion Br. J. Dermatol. (2002) 147(6):1227-1236.
69. MARCHITELLI C, SECCO G, PERROTTA M, LUGONES L, PESCE R, TESTA R: Treatment of bowenoid and basaloid vulvar intraepithelial neoplasia 2/3 with imiquimod 5% cream. J. Reprod. Med. (2004) 49(11):876-882.
70. VAN SETERS M, FONS G, VAN BEURDEN M: Imiquimod in the treatment of multifocal vulvar intraepithelial neoplasia 2/3. Results ora Pilot Study. J. Reprod. Med. (2002) 47(9):701-705.
71. LE T, HIVKD W, MENARD C, HOPKINS L, FUNG MF: Preliminary results of 5% imiquimod cream in the primary treatment of vulva intraepithelial neoplasia grade 2/3. Am. J. Obstet. Gynecol. (2006) 194(2):377-380.
72. BUCK HW, GUTH KJ: Treatment of vaginal intraepithelial neoplasia (primarily low grade) with imiquimod 5% cream. J. Low Genit. Tract Dis. (2003) 7(4):290-293.
73. HAIDOPOULOS D, DIAKOMANOLIS E, RODOLAKIS A, VOULGARIS Z, VLACHOS G, INTSAKLIS A: Can local application of imiquimod cream be an alternative mode of therapy for patients with high-grade intraepithelial lesions of the vagina? Int. J. Gynecol. Cancer (2005) 15(5):898-902.
74. DIAZ-ARRASTIA C, ARANY I, ROBAZETTI SC et al.: Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical imiquimod 5%. Clin. Cancer Res. (2001) 7(10):3031-3033.
75. PETROW W, GERSDEN R, URELICH M, RICHTER O, BIEBER T: Successful topical immunotherapy of bowenoid papulosis with imiquimod. Br. J. Dermatol. (2001) 145(6):1022-1023.
76. SMITH KJ, GERMAIN M, YEAGER J, SKELTON H: Topical 5% imiquimod for the treatment of actinic cheilitis. J. Am. Acad. Dermatol. (2002) 47(4):497-501.
77. MACKENZIE-WOOD A, KOSSARD S, DE LAUNEY JDE et al.: Imiquimod 5% cream in the treatment of Bowen's disease. J. Am. Acad. Dermatol. (2001) 44:462-470.
78. CHEN K, SHUMACK S: Treatment of Bowen's disease using a cycle regimen of imiquimod 5% cream. Clin. Exp. Dermatol. (2003) 28(Suppl. 1):10-12.
79. SMITH KJ, GERMAIN M, SKELTON H: Squamous cell carcinoma in situ (Bowen's disease) in renal transplant recipients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol. Surg. (2001) 27(6):561-564.
80. PATEL GK, GOODWIN R, CHAWLA M et al.: Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. (2006) 54(6):1025-1032.
81. PERIS K, MICANTONIOT, FARGNOLI MC, LOZZI GP, CHIMENTI S: Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma. J. Am. Acad. Dermatol. (2006) 55(2):324-327.
82. HUBER A, HUBER JD, SKINNER RB Jr, KUWAHARA RT, HAQUE R, AMONETTE RA: Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series. Dermatol. Surg. (2004) 30(3):429-430.
83. SHUMACK S, ROBINSON J, KOSSARD S: Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch. Dermatol. (2002) 138(9):1165-1171.
84. CHOONTANOM R, THANOS S, BUSSE H, STUPP T: Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study. Graefe's Arch. Clin. Exp. Ophthalmol. (2007) [Epub head of print].
85. THISSEN MR, KUIJPERS DI, KREKELS GA: Local immune modulator (imiquimod 5% cream) as adjuvant treatment after incomplete Mohs micrographic surgery for large, mixed type basal cell carcinoma: a report of 3 cases. J. Drugs Dermatol. (2006) 5(5):461-464.
86. SPENCER JM: Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. Dermatol. Surg. (2006) 32(1):63-69.
87. WU JK, OH C, STRUTTON G, SILLER G: An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. Aust. J. Dermatol. (2006) 47(1):46-48.
88. AHMED I, BERTH JONES J: Imiquimod: a novel treatment for lentigo maligna. Br. J. Dermatol. (2000) 143(4):843-845.
89. NAYLOR MF, CROWSON N, KUWAHARA R et al.: Treatment of lentigo maligna with topical imiquimod. Br. J. Dermatol. (2003) 149(Suppl. 66):66-70.
90. POWELL AM, RUSSELL-JONES R, BARLOW RJ: Topical imiquimod immunotherapy in the management of lentigo maligna. Clin. Exp. Dermatol. (2004) 29:15-21.
91. FISHER GH, LANG PG: Treatment of melanoma in situ on sun-damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease. Arch. Dermatol. (2003) 139(7):945-947.
92. RAJPAR SF, MARSDEN JR: Imiquimod in the treatment of lentigo maligna. Br. J. Dermatol. (2006) 155(2):653-656.
93. UTIKAL J, ZIMPFER A, THOELKE A et al.: Complete remission of multiple satellite and in-transit melanoma metastases after sequential treatment with isolated limb perfusion and topical imiquimod. Br. J. Dermatol. (2006) 155(2):488-489.
94. GREEN DS, BODMAN-SMITH MD, DALGLEISH AG, FISCHER MD: Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br. J. Dermatol. (2007) 156(2):337-345.
95. COORS EA, SCHULER G, VON DER DRIESCH P: Topical imiquimod as treatment of various kinds of cutaneous lymphomas. Eur. J. Dermatol. (2006) 16(4):391-393.
96. HENGGE UR, ROTH S, TANNAPFEL A: Topical imiquimod to treat recurrent breast cancer. Breast Cancer Res. Treat. (2005) 94(1):93-94.
97. LIN R, LADD DJ Jr, POWELL DJ, WAY BV: Localized pemphigus foliaceus induced by topical imiquimod treatment. Arch. Dermatol. (2005) 141(7):908-909.
98. RAJAN N, LANGTRY JA: Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas. Clin. Exp. Dermatol. (2006) 31(1):140-141.
99. FANTI PA, DIKA E, VACCARI S, MISCIAL C, VAROTTI C: Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod. Int. J. Dermatol. (2006) 45(12):1464-1465.
100. BROWN T, ZIRVI M, COTSARELIS G, GELFAND JM: Vitiligo like hypopigmentation associated with imiquimod treatment of genital warts. J. Am. Acad. Dermatol. (2005) 52(4):715-716.
101. TAYLOR GL, MASLEN M, KAPEMBWA A: A case of severe eczema following use of imiquimod 5% cream. Sex Transm. Infect. (2006) 82(3):227-228.